These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
420 related items for PubMed ID: 26899127
1. Influence of polymer molecular weight on in vitro dissolution behavior and in vivo performance of celecoxib:PVP amorphous solid dispersions. Knopp MM, Nguyen JH, Becker C, Francke NM, Jørgensen EB, Holm P, Holm R, Mu H, Rades T, Langguth P. Eur J Pharm Biopharm; 2016 Apr; 101():145-51. PubMed ID: 26899127 [Abstract] [Full Text] [Related]
2. Influence of Copolymer Composition on In Vitro and In Vivo Performance of Celecoxib-PVP/VA Amorphous Solid Dispersions. Knopp MM, Nguyen JH, Mu H, Langguth P, Rades T, Holm R. AAPS J; 2016 Mar; 18(2):416-23. PubMed ID: 26769250 [Abstract] [Full Text] [Related]
3. Effect of polymer type and drug dose on the in vitro and in vivo behavior of amorphous solid dispersions. Knopp MM, Chourak N, Khan F, Wendelboe J, Langguth P, Rades T, Holm R. Eur J Pharm Biopharm; 2016 Aug; 105():106-14. PubMed ID: 27212472 [Abstract] [Full Text] [Related]
4. Effect of amorphous phase separation and crystallization on the in vitro and in vivo performance of an amorphous solid dispersion. Knopp MM, Wendelboe J, Holm R, Rades T. Eur J Pharm Biopharm; 2018 Sep; 130():290-295. PubMed ID: 30064702 [Abstract] [Full Text] [Related]
5. Dissolution Performance of High Drug Loading Celecoxib Amorphous Solid Dispersions Formulated with Polymer Combinations. Xie T, Taylor LS. Pharm Res; 2016 Mar; 33(3):739-50. PubMed ID: 26563205 [Abstract] [Full Text] [Related]
6. Anomalous dissolution behavior of celecoxib in PVP/Isomalt solid dispersions prepared using spray drier. Ghanavati R, Taheri A, Homayouni A. Mater Sci Eng C Mater Biol Appl; 2017 Mar 01; 72():501-511. PubMed ID: 28024614 [Abstract] [Full Text] [Related]
7. Influence of PVP/VA copolymer composition on drug-polymer solubility. Rask MB, Knopp MM, Olesen NE, Holm R, Rades T. Eur J Pharm Sci; 2016 Mar 31; 85():10-7. PubMed ID: 26826280 [Abstract] [Full Text] [Related]
8. Effect of Variability of Physical Properties of Povidone K30 on Crystallization and Drug-Polymer Miscibility of Celecoxib-Povidone K30 Amorphous Solid Dispersions. Phadke C, Sharma J, Sharma K, Bansal AK. Mol Pharm; 2019 Oct 07; 16(10):4139-4148. PubMed ID: 31454247 [Abstract] [Full Text] [Related]
9. Importance of in vitro dissolution conditions for the in vivo predictability of an amorphous solid dispersion containing a pH-sensitive carrier. Wendelboe J, Knopp MM, Khan F, Chourak N, Rades T, Holm R. Int J Pharm; 2017 Oct 05; 531(1):324-331. PubMed ID: 28827200 [Abstract] [Full Text] [Related]
10. Molecular Factors Governing the Liquid and Glassy States Recrystallization of Celecoxib in Binary Mixtures with Excipients of Different Molecular Weights. Grzybowska K, Chmiel K, Knapik-Kowalczuk J, Grzybowski A, Jurkiewicz K, Paluch M. Mol Pharm; 2017 Apr 03; 14(4):1154-1168. PubMed ID: 28241116 [Abstract] [Full Text] [Related]
11. Stability and Bioavailability Enhancement of Telmisartan Ternary Solid Dispersions: the Synergistic Effect of Polymers and Drug-Polymer(s) Interactions. Shi X, Xu T, Huang W, Fan B, Sheng X. AAPS PharmSciTech; 2019 Mar 18; 20(4):143. PubMed ID: 30887265 [Abstract] [Full Text] [Related]
12. The influence of drug and polymer particle size on the in situ amorphization using microwave irradiation. Hempel NJ, Knopp MM, Berthelsen R, Zeitler JA, Löbmann K. Eur J Pharm Biopharm; 2020 Apr 18; 149():77-84. PubMed ID: 32035238 [Abstract] [Full Text] [Related]
13. Effect of Temperature and Moisture on the Physical Stability of Binary and Ternary Amorphous Solid Dispersions of Celecoxib. Xie T, Taylor LS. J Pharm Sci; 2017 Jan 18; 106(1):100-110. PubMed ID: 27476771 [Abstract] [Full Text] [Related]
14. Solution behavior of PVP-VA and HPMC-AS-based amorphous solid dispersions and their bioavailability implications. Qian F, Wang J, Hartley R, Tao J, Haddadin R, Mathias N, Hussain M. Pharm Res; 2012 Oct 18; 29(10):2765-76. PubMed ID: 22315020 [Abstract] [Full Text] [Related]
15. Formulation, characterization, and in vivo evaluation of celecoxib-PVP solid dispersion nanoparticles using supercritical antisolvent process. Ha ES, Choo GH, Baek IH, Kim MS. Molecules; 2014 Dec 04; 19(12):20325-39. PubMed ID: 25486246 [Abstract] [Full Text] [Related]
16. Supersaturated amorphous solid dispersions of celecoxib prepared in situ by microwave irradiation. Holm TP, Knopp MM, Berthelsen R, Löbmann K. Int J Pharm; 2022 Oct 15; 626():122115. PubMed ID: 35985526 [Abstract] [Full Text] [Related]
17. Understanding the generation and maintenance of supersaturation during the dissolution of amorphous solid dispersions using modulated DSC and 1H NMR. Baghel S, Cathcart H, O'Reilly NJ. Int J Pharm; 2018 Jan 30; 536(1):414-425. PubMed ID: 29183857 [Abstract] [Full Text] [Related]
18. A comparison of spray drying and milling in the production of amorphous dispersions of sulfathiazole/polyvinylpyrrolidone and sulfadimidine/polyvinylpyrrolidone. Caron V, Tajber L, Corrigan OI, Healy AM. Mol Pharm; 2011 Apr 04; 8(2):532-42. PubMed ID: 21323367 [Abstract] [Full Text] [Related]
19. Amorphous stabilization and dissolution enhancement of amorphous ternary solid dispersions: combination of polymers showing drug-polymer interaction for synergistic effects. Prasad D, Chauhan H, Atef E. J Pharm Sci; 2014 Nov 04; 103(11):3511-3523. PubMed ID: 25196860 [Abstract] [Full Text] [Related]
20. Characterization and physical stability of spray dried solid dispersions of probucol and PVP-K30. Thybo P, Pedersen BL, Hovgaard L, Holm R, Mullertz A. Pharm Dev Technol; 2008 Nov 04; 13(5):375-86. PubMed ID: 18720236 [Abstract] [Full Text] [Related] Page: [Next] [New Search]